Neurogene Inc.

Mr. Ricardo  Jimenez

Senior Vice President of Technical Operations

Ms. Christine Mikail Cvijic J.D.

President, Chief Financial Officer & Corporate Secretary

Mr. Arvind  Sreedharan

Senior Vice President of Business Operations

Dr. Stuart  Cobb Ph.D.

Chief Scientific Officer

Dr. Effie  Albanis M.D.

Senior Vice President of Early Clinical & Translational Research

Dr. Andrew E. Mulberg CPI, FAAP, M.D.

Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control

Dr. Rachel L. McMinn Ph.D.

Founder, Executive Chair & Chief Executive Officer

Ms. Donna M. Cochener-Metcalfe J.D.

Senior Vice President & General Counsel

Dr. Julie  Jordan M.D.

Chief Medical Officer

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates. “We are pleased that NGN-401 gene therapy for Rett syndrome received RMAT designation, in addition to the recent selection by the U.S. FDA for its START Pilot Program, two programs that provide distinct opp.

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that NGN-401 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Rett syndrome. The designation was based on preliminary clinical evidence from the ongoing Phase 1/2 clinical trial with NGN-401 that sh.

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on.

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Goldman Sachs 45th Annual Global Healthcare Conference Format: Management will present a corporate overview and participate in investor meetings Date: Wednesday, June 12 at 1:20 p.m. ET 2024 IRSF (International Rett.

Neurogene to Participate in Upcoming Conferences

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the U.S. Food and Drug Administration (FDA) Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. As part of the START Program, Neurogene will have opportunities for enh.

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

Neurogene Inc.NGNE

Neurogene Inc.
NGNE